Invokana Tablet, Film Coated
Product Images NDC 50458-140

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Invokana (NDC 50458-140). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Janssen Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Invokana 01)

Chemical structure of canagliflozin showing its molecular arrangement including a fluorophenyl group, a thiophene ring, and a glucose moiety with hydroxyl groups. The image also indicates the presence of half a water molecule as a hydrate component.*

FDA Label Image

Figure 1 (Invokana 02)

A line graph displaying the least squares mean change in HbA1c (%) from baseline over 52 weeks of study with standard error bars. It compares the effects of canagliflozin 100 mg, canagliflozin 300 mg, and glimepiride on HbA1c levels, showing a decrease over time for all three treatments.*

FDA Label Image

Figure 2 (Invokana 03)

A line graph comparing the least squares mean change in HbA1c (%) from baseline over a 52-week study period between Canagliflozin 300 mg and Sitagliptin 100 mg. The x-axis shows study weeks, and the y-axis shows changes in HbA1c with standard error bars. Both treatments show a decrease that stabilizes over time, with Canagliflozin generally maintaining a greater reduction.*

FDA Label Image

Figure 3 (Invokana 04)

A line graph comparing the percentage of subjects with events over time in weeks between canagliflozin (Cana, dotted line) and placebo (solid line). The x-axis represents time in weeks (0 to 338), and the y-axis shows the percentage of subjects with events (0 to 24%). Numbers of subjects at risk are listed below the x-axis for both placebo and canagliflozin groups. The graph includes a hazard ratio (HR 0.86 with 95% CI 0.75 to 0.97) for Cana versus placebo.*

FDA Label Image

Figure 4 (Invokana 05)

A Kaplan-Meier curve showing the percentage of subjects with events over time (in weeks) comparing canagliflozin (Cana) versus placebo. The graph includes hazard ratio (HR 0.70, 95% CI 0.59 to 0.82). The x-axis represents time in weeks, and the y-axis represents the percentage of subjects with events. A table below shows the number of subjects at risk for both groups at various time points.*

FDA Label Image

Principal Display Panel (100 mg Tablet Bottle Label)

Invokana 100 mg film-coated tablets packaging label showing the proprietary name Invokana with generic name canagliflozin. The label indicates a package of 90 tablets, oral route, manufactured by Janssen Pharmaceuticals, Inc. It includes medication guide dispensing instructions and storage information. The label features NDC 50458-140-90 and a yellow tablet image labeled 100 mg.*

FDA Label Image

Principal Display Panel (300 mg Tablet Bottle Label)

Label for Invokana (canagliflozin) tablets with a strength of 300 mg. The film-coated tablets are supplied by Janssen Pharmaceuticals, Inc. The label indicates a package count of 90 tablets for oral use. It includes dispensing instructions and storage temperature guidelines, along with a white tablet imprinted with '300'.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.